Table 2.

Transgene expression and onset of tumors in MMTV/MT-Y315/322F micea

LineExpression of transgeneb in:Avg onset of mammary tumors (days)cTumor types and hyperplasias
M.Gl.T (female)m.Gl.NSal.Epidid.Sem. Ves.Testes
FemaleMale
Db-1++++255 (17)M.Gl. adenocarcinomas
Db-2 (founder)NANDNDNDNDNDNDNoneNone
Db-3++++/−NDNDNDND253 (15)M.Gl. adenocarcinomas
Db-4++++++++120 (70)M.Gl. adenocarcinomas, salivary/parotid neoplasms?, early developmental failure to arborize fat pad
Db-5++++++++++++++++107 (55)M.Gl. adenocarcinomas, salivary/parotid neoplasms?, early developmental failure to arborize fat pad
Db-6++++∼200M.Gl. adenocarcinomas
Db-7 (founder)+++NANANDNANANA65 (1)M.Gl. adenocarcinomas
  • a RNase protection analysis was performed on 20 μg of total RNA isolated from a variety of organs in the MMTV/MT-Y315/322F strains as described in Materials and Methods.

  • b Relative levels of transgene expression (as determined by quantitative phosphorimager analysis): −, not detected; +, low; ++, intermediate; +++, high. M.Gl.N, normal mammary gland; M.Gl.T, mammary gland tumor; Sal., salivary gland; Epidid., epididymus; Sem. Ves.; seminal vesicles; NA, not applicable; ND, not determined.

  • c The number of animals analyzed is given in parentheses.